Showing results (591-600 of 646) with videos related to
Sort By:
Pageof 65
Gastroenterology|July 6, 2010
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3David R Nelson, Yves Benhamou, Wan-Long Chuang, et al.Liver International : Official Journal of the International Association for the Study of the Liver|January 2, 2021
Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP studyMarina Serper, Donna M Evon, Jipcy Amador, et al.Gastroenterology|August 28, 2016
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic ResponseNorah A Terrault, Stefan Zeuzem, Adrian M Di Bisceglie, et al.Scientific Reports|March 10, 2019
Similarities, variations, and evolution of cytochrome P450s in Streptomyces versus MycobacteriumLouisa Moshoeshoe Senate, Martin Phalane Tjatji, Kayla Pillay, et al.Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 1, 2015
Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research networkRobert S Brown, Jacqueline G O'Leary, K Rajender Reddy, et al.Journal of General Internal Medicine|October 30, 2019
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting AntiviralsMarina Serper, Donna M Evon, Paul W Stewart, et al.The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.Journal of Hepatology|May 23, 2021
Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvirGary P Wang, Gretja L Schnell, Jens J Kort, et al.Hepatology (Baltimore, Md.)|May 16, 2017
Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET studyVarun Saxena, Vandana Khungar, Elizabeth C Verna, et al.Gastroenterology|October 27, 2015
Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 InfectionMark S Sulkowski, Hugo E Vargas, Adrian M Di Bisceglie, et al.Pageof 65